Meta-analysis of dropout rates in SSRIs versus placebo in randomized clinical trials of PTSD

Journal of Nervous and Mental Disease

Volumn 198, Issue 2, 2010, Pages 116-124

  Lurie, Ido ^a   Levine, Stephen Z ^b  

^a SHALVATA MENTAL HEALTH CENTER   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

Clinical trial; Dropout; Meta analysis; PTSD

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; HUMAN; INJURY; META ANALYSIS; POSTTRAUMATIC STRESS DISORDER; PREDICTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

DRUG THERAPY; HUMANS; PATIENT DROPOUTS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, POST-TRAUMATIC;

EID: 76949095652     PISSN: 00223018     EISSN: None     Source Type: Journal    
DOI: 10.1097/NMD.0b013e3181cc41b6     Document Type: Article

References (75)

1. American Psychiatric Association (2000) Diagnostic Criteria from DSM-IV-TR. Washington (DC): American Psychiatric Association.
2. Back SE, Brady KT, Sonne SC, Verduin ML (2006) Symptom improvement in co-occurring PTSD and alcohol dependence. J Nerv Ment Dis. 194:690-696.
3. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM (2000) Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial. JAMA. 283:1837-1844.
4. Brady KT, Sonne S, Anton RF, Randall CL, Back SE, Simpson K (2005) Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res. 29:395-401.
5. Brady KT, Sonne SC, Roberts JM (1995) Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J Clin Psychiatry. 56: 502-505.
6. Breslau N, Davis GC, Andreski P, Peterson E (1991) Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry. 48:216-222.
7. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR (1999) Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br J Psychiatry. 175:17-22.
8. Creamer M, Burgess P, McFarlane AC (2001) Post-traumatic stress disorder: Findings from the Australian National Survey of Mental Health and Wellbeing. Psychol Med. 31:1237-1247.
9. Davidson JR, Connor KM, Hertzberg MA, Weisler RH, Wilson WH, Payne VM (2005) Maintenance therapy with fluoxetine in posttraumatic stress disorder: A placebo-controlled discontinuation study. J Clin Psychopharmacol. 25:166-169.
10. Davidson J, Pearlstein T, Londborg P, Brady KT, Rothbaum B, Bell J, Maddock R, Hegel MT, Farfel G (2001a) Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: Results of a 28-week double-blind, placebocontrolled study. Am J Psychiatry. 158:1974-1981.
11. Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ (2006) Venlafaxine extended release in posttraumatic stress disorder: A sertraline-and placebo-controlled study. J Clin Psychopharmacol. 26:259-267. (Pubitemid 43804617)
12. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM (2001b) Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 58:485-492.
13. Davidson JR, Weisler RH, Malik M, Tupler LA (1998) Fluvoxamine in civilians with posttraumatic stress disorder. J Clin Psychopharmacol. 18:93-95. (Pubitemid 28045646)
14. Davis LL, Suris A, Lambert MT, Heimberg C, Petty F (1997) Post-traumatic stress disorder and serotonin: New directions for research and treatment. J Psychiatry Neurosci. 22:318-326.
15. Deykin EY, Keane TM, Kaloupek D, Fincke G, Rothendler J, Siegfried M, Creamer K (2001) Posttraumatic stress disorder and the use of health services. Psychosom Med. 63:835-841.
16. Escalona R, Canive JM, Calais LA, Davidson JR (2002) Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depress Anxiety. 15:29-33.
17. Fichtner CG, Arora RC, O'Connor FL, Crayton JW (1994) Platelet paroxetine binding and fluoxetine pharmacotherapy in posttraumatic stress disorder: Preliminary observations on a possible predictor of clinical treatment response. Life Sci. 54:PL39-PL44.
18. Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM (2007) Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 68:711-720.
19. Helzer JE, Robins LN, McEvoy L (1987) Post-traumatic stress disorder in the general population. Findings of the epidemiologic catchment area survey. N Engl J Med. 317:1630-1634.
20. Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR (2000) Lack of efficacy for fluoxetine in PTSD: A placebo controlled trial in combat veterans. Ann Clin Psychiatry. 12:101-105.
21. Kawahara Y, Kawahara H, Kaneko F, Tanaka M (2007) Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain. Psychopharmacology (Berl). 194:73-81.
22. Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW (2005) Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: A meta-analysis. Arch Gen Psychiatry. 62:1305-1312.
23. Kessler RC (2000) Posttraumatic stress disorder: The burden to the individual and to society. J Clin Psychiatry. 61(suppl 5):4 -12; discussion 13-14.
24. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB (1995) Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 52:1048-1060.
25. Khan A, Schwartz K, Redding N, Kolts RL, Brown WA (2007) Psychiatric diagnosis and clinical trial completion rates: Analysis of the FDA SBA reports. Neuropsychopharmacology. 32:2422-2430.
26. Kim Y, Asukai N, Konishi T, Kato H, Hirotsune H, Maeda M, Inoue H, Narita H, Iwasaki M (2008) Clinical evaluation of paroxetine in post-traumatic stress disorder (PTSD): 52-week, non-comparative open-label study for clinical use experience. Psychiatry Clin Neurosci. 62:646-652.
27. Kline NA, Dow BM, Brown SA, Matloff JL (1994) Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder. Am J Psychiatry. 151:621.
28. Liebschutz J, Saitz R, Brower V, Keane TM, Lloyd-Travaglini C, Averbuch T, Samet JH (2007) PTSD in urban primary care: High prevalence and low physician recognition. J Gen Intern Med. 22:719-726.
29. Londborg PD, Hegel MT, Goldstein S, Goldstein D, Himmelhoch JM, Maddock R, Patterson WM, Rausch J, Farfel GM (2001) Sertraline treatment of posttraumatic stress disorder: Results of 24 weeks of open-label continuation treatment. J Clin Psychiatry. 62:325-331. (Pubitemid 32545552)
30. Lumley T (2009) rmeta: Meta-analysis. R package version 2.16. http://CRAN. R-project.org/package-meta.
31. Maes M, Lin AH, Verkerk R, Delmeire L, Van Gastel A, Van der Planken M, Scharpe S (1999) Serotonergic and noradrenergic markers of post-traumatic stress disorder with and without major depression. Neuropsychopharmacology. 20:188-197.
32. Malik ML, Connor KM, Sutherland SM, Smith RD, Davison RM, Davidson JR (1999) Quality of life and posttraumatic stress disorder: A pilot study assessing changes in SF-36 scores before and after treatment in a placebo-controlled trial of fluoxetine. J Trauma Stress. 12:387-393.
33. Marshall RD, Beebe KL, Oldham M, Zaninelli R (2001) Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. Am J Psychiatry. 158:1982-1988.
34. Marshall RD, Lewis-Fernandez R, Blanco C, Simpson HB, Lin SH, Vermes D, Garcia W, Schneier F, Neria Y, Sanchez-Lacay A, Liebowitz MR (2007) A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Depress Anxiety. 24:77-84.
35. Marshall RD, Schneier FR, Fallon BA, Knight CB, Abbate LA, Goetz D, Campeas R, Liebowitz MR (1998) An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol. 18:10-18.
36. Martenyi F, Brown EB, Caldwell CD (2007) Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: Results of a fixed-dose, placebocontrolled study. J Clin Psychopharmacol. 27:166-170.
37. Martenyi F, Brown EB, Zhang H, Koke SC, Prakash A (2002a) Fluoxetine vs. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry. 181:315-320.
38. Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC (2002b) Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry. 63:199-206.
39. Martenyi F, Soldatenkova V (2006) Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: Analysis of the veteran group of a placebo-controlled, randomized clinical trial. Eur Neuropsychopharmacol. 16:340-349.
40. McDougle CJ, Southwick SM, Charney DS, St James RL (1991) An open trial of fluoxetine in the treatment of posttraumatic stress disorder. J Clin Psychopharmacol. 11:325-327.
41. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of reporting of meta-analyses. Lancet. 354: 1896-1900.
42. Nagy LM, Morgan CA III, Southwick SM, Charney DS (1993) Open prospective trial of fluoxetine for posttraumatic stress disorder. J Clin Psychopharmacol. 13:107-113.
43. Neria Y, Nandi A, Galea S (2008) Post-traumatic stress disorder following disasters: A systematic review. Psychol Med. 38:467-480.
44. Rabinowitz J, Davidov O (2008) The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull. 34:286-291.
45. Rabinowitz J, Levine SZ, Barkai O, Davidov O (2009) Dropout rates in randomized clinical trials of antipsychotics: A meta-analysis comparing first-and second-generation drugs and an examination of the role of trial design features. Schizophr Bull. 35:775-788.
46. Rapaport MH, Endicott J, Clary CM (2002) Posttraumatic stress disorder and quality of life: Results across 64 weeks of sertraline treatment. J Clin Psychiatry. 63:59-65.
47. Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL (2006) Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry. 67:1522-1526.
48. Rothbaum BO, Cahill SP, Foa EB, Davidson JR, Compton J, Connor KM, Astin MC, Hahn CG (2006) Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Trauma Stress. 19:625-638.
49. Rothbaum BO, Ninan PT, Thomas L (1996) Sertraline in the treatment of rape victims with posttraumatic stress disorder. J Trauma Stress. 9:865-871.
50. Roy-Byrne PP, Perera P, Pitts CD, Christi JA (2005) Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: A pooled analysis. J Clin Psychiatry. 66:1228-1233.
51. Schottenbauer MA, Glass CR, Arnkoff DB, Tendick V, Gray SH (2008) Nonresponse and dropout rates in outcome studies on PTSD: Review and methodological considerations. Psychiatry. 71:134-168.
52. Shalev A, Bleich A, Ursano RJ (1990) Posttraumatic stress disorder: Somatic comorbidity and effort tolerance. Psychosomatics. 31:197-203.
53. Simon NM, Connor KM, Lang AJ, Rauch S, Krulewicz S, LeBeau RT, Davidson JR, Stein MB, Otto MW, Foa EB, Pollack MH (2008) Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry. 69:400-405.
54. Smajkic A, Weine S, Djuric-Bijedic Z, Boskailo E, Lewis J, Pavkovic I (2001) Sertraline, paroxetine and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. J Trauma Stress. 14:445-452.
55. Solomon Z (1988) Somatic complaints, stress reaction and posttraumatic stress disorder: A three-year follow-up study. Behav Med. 14:179-185.
56. Southwick SM, Krystal JH, Bremner JD, Morgan CA III, Nicolaou AL, Nagy LM, Johnson DR, Heninger GR, Charney DS (1997) Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry. 54:749-758.
57. Spiro A III, Hankin CS, Mansell D, Kazis LE (2006) Posttraumatic stress disorder and health status: The veterans health study. J Ambul Care Manage. 29:71-86.
58. Spivak B, Strous RD, Shaked G, Shabash E, Kotler M, Weizman A (2006) Reboxetine versus fluvoxamine in the treatment of motor vehicle accidentrelated posttraumatic stress disorder: A double-blind, fixed-dosage, controlled trial. J Clin Psychopharmacol. 26:152-156.
59. Stein DJ, Davidson J, Seedat S, Beebe K (2003) Paroxetine in the treatment of post-traumatic stress disorder: Pooled analysis of placebo-controlled studies. Expert Opin Pharmacother. 4:1829-1838.
60. Stein DJ, Ipser J, McAnda N (2009) Pharmacotherapy of posttraumatic stress disorder: A review of meta-analyses and treatment guidelines. CNS Spectr. 14:25-31.
61. Stein DJ, Ipser JC, Seedat S (2006) Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. CD002795.
62. Stein MB, McQuaid JR, Pedrelli P, Lenox R, McCahill ME (2000) Posttraumatic stress disorder in the primary care medical setting. Gen Hosp Psychiatry. 22:261-269.
63. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA (2003) The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophr Bull. 29:15-31.
64. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC (2003) Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull. 29:33-43.
65. Szabo ST, de Montigny C, Blier P (2000) Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol. 3:1-11.
66. Team RDC (2006) R: A Language and Environment for Statistical Computing. Vienna (Austria): R Foundation for Statistical Computing.
67. Tucker P, Beebe KL, Burgin C, Wyatt DB, Parker DE, Masters BK, Nawar O (2004) Paroxetine treatment of depression with posttraumatic stress disorder: Effects on autonomic reactivity and cortisol secretion. J Clin Psychopharmacol. 24:131-140.
68. Tucker P, Potter-Kimball R, Wyatt DB, Parker DE, Burgin C, Jones DE, Masters BK (2003) Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline and placebo. Psychopharmacol Bull. 37:135-149.
69. Tucker P, Smith KL, Marx B, Jones D, Miranda R, Lensgraf J (2000) Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorder. J Clin Psychopharmacol. 20:367-372.
70. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD (2001) Paroxetine in the treatment of chronic posttraumatic stress disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 62:860-868. (Pubitemid 33131172)
71. van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G (1994) Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry. 55: 517-522.
72. van der Kolk BA, Spinazzola J, Blaustein ME, Hopper JW, Hopper EK, Korn DL, Simpson WB (2007) A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine and pill placebo in the treatment of posttraumatic stress disorder: Treatment effects and long-term maintenance. J Clin Psychiatry. 68:37-46.
73. Viechtbauer, W. (2006). MiMa: An S-Plus/R function to fit meta-analytic mixed-, random-, and fixed-effects models [Computer software and manual]. [computer program]. Version; 2006.
74. Zatzick DF, Marmar CR, Weiss DS, Browner WS, Metzler TJ, Golding JM, Stewart A, Schlenger WE, Wells KB (1997) Posttraumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans. Am J Psychiatry. 154:1690-1695. (Pubitemid 27516585)
75. Zohar J, Amital D, Miodownik C, Kotler M, Bleich A, Lane RM, Austin C (2002) Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol. 22:190-195.